Start Date
June 30, 2008
Primary Completion Date
June 30, 2009
Study Completion Date
October 31, 2009
AMG 108
IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
Placebo
AMG 108 volume matching placebo
Lead Sponsor
Amgen
INDUSTRY